questions that have been raised here, as well as to the other issues which we believe merit the committee's consideration.3

Senator Nelson. Let me interrupt just to say that our problem with the third day is that it appears that Congress may be running into December. And if we are—which I think we will—then we will be at the tail end of a heavy session, and going from 10 o'clock in the morning straight on through the day. And I cannot very well handle a hearing under those circumstances because some of the most important bills will be before us.

Mr. Stetler. I appreciate that. I think if we just can get across that we have really gotten a lot of people prepared, and there are studies in depth that have been done, that we would like the opportunity to get into the hearing, and whether that is in December or

January—just so we have that opportunity.

Senator Nelson. You will have the opportunity if it takes 5 days of hearings or 10 or whatever length of time it takes, to cover all the material on all the issues, so that you won't feel that the industry has

been discriminated against.

Mr. Stetler. As far as today is concerned, as you know, as you have mentioned, in addition to the lengthier prepared statements, we have submitted for inclusion in the record some of the studies—and I am not now referring to the supplemental statement that was just discussed—but material that was submitted as of the 6th of November. We would like to have that made a part of the record of today's hearings.

Senator Nelson. I have not had a chance to go through all those. I will look at them and see. I do not know how necessary you feel they

are.

Mr. Stetler. We do think they are necessary, sir, and we would like to have them part of the record.

Senator Nelson. If they are a useful part of the record, I will put

them in. I have not studied those. I don't know what is in them.

Mr. Stetler. There is a lot of material that we have gone to a lot of trouble and expense to prepare. And I hope you will see fit to put it in the record.

Senator Nelson. I will put it in. I have not had a chance to go through it all. But we will put it in the record.

Mr. Stetler. They were submitted on the 6th. That is part of attachments to our statements today.

Senator Nelson. All right, proceed.

Mr. Stetler. The PMA witnesses who follow me today and later will comment in greater detail on some of the points I am going to touch on briefly in my statement. We will deal with the issues of prescribing and dispensing drugs by their generic names, and will discuss drug prices and profits. We will deal with research trends and expenditures. We will discuss the high-risk characteristics of the pharmaceutical industry and its need to attract capital for growth and for continued health progress. We will also discuss the vital aspects of produc-

<sup>&</sup>lt;sup>3</sup> The statements of Dr. Leslie M. Lueck, Dr. A. E. Slesser, Dr. Leonard A. Scheele, Dr. Hart E. Van Riper, and Leland W. Blazey, originally scheduled for appearance with Mr. Stetler, appear in hearing date, Wednesday, Nov. 29, 1967, Competitive Problems in the Drug Industry, pt. 5.

<sup>4</sup> Material retained in files of committee's record of the hearings.